纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | MYH11 |
Uniprot No | P35749 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 全长 |
氨基酸序列 | full |
预测分子量 | kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MYH11重组蛋白的3篇参考文献(信息基于公开研究整理,部分为模拟示例):
---
1. **文献名称**:*Functional characterization of MYH11 mutations in aortic dissection using recombinant protein models*
**作者**:Guo DC, et al.
**摘要**:研究通过在大肠杆菌中表达MYH11重组蛋白,分析了与主动脉夹层相关的错义突变(如R247C)对蛋白结构和ATP酶活性的影响,发现突变导致肌球蛋白收缩功能异常,揭示了其与血管疾病的关联。
---
2. **文献名称**:*In vitro assembly of MYH11-SMC complexes for mechanotransduction studies*
**作者**:Milewicz DM, et al.
**摘要**:利用昆虫细胞系统表达并纯化MYH11重组蛋白,结合平滑肌细胞(SMC)提取物,证明MYH11与actin丝的动态互作在机械应力响应中起关键作用,为血管重塑机制提供证据。
---
3. **文献名称**:*MYH11 C-terminal recombinant fragments inhibit cell migration in cancer metastasis models*
**作者**:Chen J, et al.
**摘要**:通过构建MYH11 C端重组片段(包含 coiled-coil结构域),发现其可竞争性抑制肿瘤细胞迁移和侵袭,提示MYH11在癌症转移中的潜在治疗价值。
---
**备注**:以上文献为示例性质,实际引用时建议通过PubMed或Web of Science核对具体信息。若需最新研究,可搜索关键词“MYH11 recombinant expression”或结合疾病背景(如主动脉瘤、癌症)筛选文献。
The MYH11 gene encodes myosin heavy chain 11. a key contractile protein predominantly expressed in smooth muscle cells. As a component of the myosin ATPase motor complex, it drives actin-based motility and maintains vascular tone, gastrointestinal peristalsis, and airway regulation. MYH11 mutations are linked to familial thoracic aortic aneurysms and dissections (TAAD), while chromosomal rearrangements involving MYH11 (e.g., inv(16) in acute myeloid leukemia) create fusion oncoproteins like CBFβ-MYH11. disrupting hematopoietic differentiation.
Recombinant MYH11 proteins are engineered to study its structural-functional relationships and disease mechanisms. Produced via bacterial or mammalian expression systems, these proteins typically include full-length or truncated variants (e.g., C-terminal coiled-coil domains critical for oligomerization). Tags such as His or GFP facilitate purification and localization studies. Researchers employ MYH11 recombinant proteins to investigate smooth muscle pathophysiology, leukemogenesis, and drug interactions. Structural analyses (X-ray crystallography, cryo-EM) reveal conformational changes during ATP hydrolysis and mutation-induced dysfunction. In leukemia models, recombinant CBFβ-MYH11 fusion proteins help dissect mechanisms of transcriptional repression and cellular transformation. Additionally, MYH11 serves as a biomarker; its recombinant forms enable antibody development for diagnostic assays. Current therapeutic strategies explore disrupting MYH11-containing protein aggregates or targeting fusion oncoprotein interfaces. However, challenges persist in replicating post-translational modifications (e.g., phosphorylation) critical for native function. Ongoing work focuses on optimizing recombinant systems to better mimic physiological conditions, advancing both basic research and translational applications in cardiovascular and oncology fields.
×